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Abstract 
Title: Pharmacological and Non-Pharmacological Interventions for the Management of Fatigue 
Related Multiple Sclerosis: A Review of Reviews  
Aim:  The clinical aim was to provide up-to-date evidence-based recommendations for the treatment 
of 
 MS-related fatigue (MSRF). The scientific aim was to prioritize topics for future randomized clinical 
trials with sufficient power.The clinical aim: to provide up-to-date evidence-based recommendations for the 
treatment of 
MS-related fatigue; and the scientific aim: …to prioritize topics for future randomized clinical trials with 
sufficient power. 
Methods: A systematic search of review based research that considered MSRF in adults (18 years and 
over) was undertaken in May 2016. Data from reviews was extracted, critically appraised and 
synthesised using four specific techniques. 
Results: A total of 24 reviews were identified (17 non-pharmacological, 5 pharmacological, 2 
combining both), which contained 339 studies on interventions deigned to improve MSRF. The 
methodological quality of the reviews was identified by an average AMSTAR score of 6.5 (SD=1.87: 
95% CI=5.75-7.25).  
No pharmacological intervention had strong evidence for improving MSRF. Limited/ conflicting 
evidence was found for Amantadine and Prokarin and potential benefits for Modafinil were identified. 
Pemoline and Carnitine contained unclear/no evidence for fatigue management.  
Non-pharmacological interventions produced mixed conclusions regarding the effectiveness of the 
intervention to improve MSRF. Education (energy conservation and fatigue management) and exercise 
had supporting evidence for reducing MSRF but mixed conclusions gathered from subtypes of 
exercise. Reviews considering psycho-behavioural interventions (CBT and mindfulness) had limited 
information considering effectiveness. Finally, a single intervention combining physical and cognitive 
strategies showed more promising results. 
Conclusion: Further research into Pharmacological interventions for MSRF is required notably 
considering the potential of Modafinil. Yoga, resistance and endurance training and energy 
conservation/fatigue management programs  had strong evidence supporting use in management of 
MSRF. Due to the dissimilar interventions used in combined training the subtype of exercise cannot be 
recommended.  despite initially concluding with “high  Futureconfidence” Future research into 
Amantadine, psycho-behavioural interventions and aerobic endurance exercise is vital to justify the 
current National Institute for Health and Care Excellence NICE guidelines. The methodological 
quality of studies inhibited the ability of this review to provide other recommendations. 
 
 
Comment [AS1]: Need for capitals? 
Comment [AS2]: You give guidelines 
for endurance below – check  
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1:1.1 Introduction 
Multiple Sclerosis related fatigue (MSRF) is reported in 70-80% of the MS population and over 55% 
of patients report fatigue as the worse symptom experienced from MS
1
. Compared to age and gender 
match controls, people who experience MSRF combined with other symptoms have significantly 
increased disability, reduced quality of life (physical and mental)
2
 and reduced experiences of daily 
living3. For the purposes of this review we classify MSRF as fatigability (increased weakness after 
exercise or over the course of the day) or lassitude (abnormal feeling of constant tiredness))12. The 
main treatment for MSRF can be broadly classified as pharmacological or non-pharmacological and 
treatment for MSRF is directed by clinical guidelines e.g., in the UK by the National Institute for 
Health and Care Excellence National Institute of Clinical Excellence (NICE)44.   
Currently At present, amantadine is the only drug supported by the National Institute for Health and 
Care Excellence NICE guidelines for the pharmacological management of MSRF
4
. However, 
Prokarin is listed as an alternative medication, however only limited evidence justifies its 
effectiveness for treating MSRF
5
. Finally, Modafinil is not consistently licensed across westernised 
countries e.g., it is not currently licensed for the treatment of MSRF in the UK6. One reason for this 
may be that Wwhilst some studies
7
 have identified improvement in MSRF Methodological weakness 
and inadequate sample size of studies inhibit the ability to be conclusive about the results the clinical 
evidence of the data is supporting the positive correlation significantly weak.  
The National Institute for Health and Care Excellence NICE guidelines4 advise education (energy 
conservation), exercise (aerobic, resistance and yoga) and psycho-behavioural techniques (Cognitive 
Behavioural Therapy (CBT) or mindfulness) as part of the non-pharmacological management of 
MSRF. Current rReview evidence has identified short-term benefits of energy conservation on bio-
psychosocial outcomes for patients with MSRF8. Many reviews have examined the effects of exercise 
on MSRF, however the heterogeneity of outcome measures used makes direct comparison between 
results difficult
9
. Prevailing Current research has not fully examined the effect of CBT on MSRF
10
. 
Mindfulness programs including tai-chi, yoga, relaxation and meditation found significant 
improvements in MSRF11,1211. Thus, evidence considering different non-pharmacological approaches 
requires further systematic consideration and synthesis. 
Given the high volumes of the past review evidence across pharmacological and behavioural 
approaches that treat MSRF an overview review of recent evidence is required.  To the best of the 
author’s knowledge , to date, no review of reviews systematic overview of all approaches has been 
conducted. This review of reviews will summarise both pharmacological and non-pharmacological 
interventions for MSRF using novel synthesis techniques to provide clear intervention 
recommendations and provide prescription of treatment. Thus tThe aims of this research is to provide 
a review of reviews that includes pharmacological and non-pharmacological reviews and to establish 
recommendations for the clinical treatment of MSRF.were to provide up-to-date evidence-based 
recommendations for the treatment of MS-related fatigue and to prioritise topics for future 
randomised clinical trials with sufficient power. 
Methodology 
Materials and Methods 
An adapted PRISMA statement
123
 was used to guide the systematic search processes and reporting. 
Eligibility criteria 
The following eligibility criteria was applied focusing on the eligibility criteria of the included 
reviews: 
Comment [AS3]: Reword do you 
mean  
Methodological weakness and 
inadequate sample size of studies 
inhibit the ability to be conclusive 
about the results. 
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 Population: Any group or sub-group (e.g., all sub-types of MS and in or outpatients, any time 
since diagnosis) of patients with MS was included. Note, a focus on the subtypes of MS is 
often lacking in review-based research
143
. Reviews with multiple population groups were 
excluded unless a clear and separate analysis on patients with MS was undertaken.  
 Participants: Male and female adults 18 years old and above were included. Paediatric 
patients were excluded due to physiological differences and alternative interventions often 
used
145
. No animal studies were included. 
 Intervention: Any pharmacological or non-pharmacological interventions designed to 
improve MSRF were included. Reviews that focused on interventions where treatment of 
MSRF was not a central or primary component were excluded.  
 Comparison Group: Reviews were required to include education (active control) or no 
intervention (in-active control) to prevent a confounding bias
143
. 
 Outcome Measures: Studies were included if a fatigue outcome measure or a measure of 
fatigue as a sub-domain of an outcome measure was used. A list of appropriate outcome 
measures can be seen in the Supplementary File.    
 Study design: Any traditional quantitative systematic review focusing on effectiveness of 
treatments for MSRF from a peer-reviewed journal was included. Qualitative data was not 
included due to the focus on assessing effectiveness. 
 Other criteria: (1) Time frame: Reviews from 2000 onwards were included. All relevant 
interventions pre 2000pre-2000 we considered to be captured in the review evidence 
included
5
 (2) Language: Reviews not written in English were excluded. (3) Grey literature: 
Unpublished reviews and conference proceedings were not included. 
Search Strategy  
Electronic databases were independently searched by blind researchers (PM, AS) from inception until 
May 2016. The following electronic databases were chosen; The Cochrane Library
15
,CINAHL
16
, 
CINAHL
176,17
, PubMed/Medline
178
, and Web of Science
18,19
. Pre-defined search terms with Boolean 
operators included: Multiple Sclerosis OR MS AND FATIGUE OR TIREDNESS OR 
EXHAUSTION OR LETHARGY OR LASSITUDE AND TREATMENT OR INTERVENTION OR 
EXPERIENCE AND REVIEW OR SYSTEMATIC REVIEW AND MEDICATION OR 
ALTERNATIVE THERAPY OR COMPLEMENTARY THERAPY OR THERAPY OR EXERCISE 
OR PHYSICAL ACTIVITY. Other search mechanisms included searching the reference lists of 
included reviews, searching the first 20 hits from pages of Google scholar and sciencedirect.com, and 
searching included author home research web pages. See Supplementary file for excluded reviews. 
Study selection 
Data extraction and collection procedures 
Independent assessment of selected articles by PM/AS was undertaken when considering articles by 
title, abstract and full text. A third researcher could be contacted to arbitrate discussions where 
inclusion was not agreed. No arbitration was required.  
PM collected data from each review including demographical information, methods, outcome 
measures of fatigue, number/type of studies, interventions and the results.  
Critical appraisal of reviews  
The AMSTAR (Assessment of the Methodological Quality of a Systematic Review) tool19 and 
SALSA (Search, Appraisal, Synthesis and Analysis) tool20 were used to assess the methodological 
quality of the systematic reviews. Both were combined to create a form used to assess quality (see 
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Supplementary File). The assessment of risk of bias conducted by reviews were grouped and a tabular 
of summary risk of bias created confirming with Cochrane’s Collaboration Tool for Assessing Risk of 
Bias (See Supplementary File)
21
. A separate and combined grading analysis tool was created by PM 
(see Table 1) and allowed overall assessment of review quality as ‘poor’, ‘fair’, and ‘good’ within the 
below text. .  The grading analysis tool was used to create confidence related statements by combining 
this data with the number of studies with supporting evidence from an intervention type. Three 
confidence and recommendation statements about intervention types were made including to use the 
intervention, (a) ‘with caution’, (b) ‘with confidence’ and (c) ‘with high confidence’ (See footnote in 
Supplementary File). 
Domain of 
consideration  
Overall Assessment Grade given to Review 
Poor Fair Good 
Outcome 
Measures 
50% of outcomes have 
poor reliability and 
validity. 
50% of outcomes have 
adequate reliability and 
validity.  
90% outcomes have strong 
reliability and validity. Validation 
studies undertaken in Multiple 
Sclerosis populations.  
Key Domains 1-2 domains 3-4 domains 5-6 domains 
Results Results contain no 
statistics and results are 
vague and unclear 
Results contain some 
statistics and numeral value. 
Results contain statistics, statistical 
analysis and meta-analysis 
Risk of Bias Unclear/N/A / High Moderate, Moderate-High, 
Moderate-Low 
Low 
AMSTAR 0-4 Scoring 5-8 scoring 9-11 scoring 
 
Table 1 Grading and review assessment criteria 
 
Narrative Synthesis Processes  
Two primarily synthesis techniques were used: (1) Tabulation was the main method of analysis in this 
review including a summary table of the included studies, listing of interventions and their results, 
outcome measures and methods22. (2) Translation of review findings was used to evaluate the key 
findings found from the results from each review to reach an overall conclusion that acted as the basis 
for recommendations. We document tTwo further analysis techniques are includeding in the 
Supplementary File, this includes an event timeline was used to map the spread of reviews on 
interventions to view changes or trends in the literature and a taxonomic analysis that groups MSRF 
outcome measures together in order toto identify the key MSRF domains232. Please note a traditional 
meta-analysis was not possible due to the heterogeneity of the data. 
Results 
Analysis of Evidence 
Twenty-four reviews (195 339 studies (Total number 324:129 duplicates)) were used in the data 
analysis (17 non-pharmacological, 5 pharmacological, 2 combining both) were included. The reviews 
were most often classified as systematic (n=19) or quantitative (n=11). A total of 19 reviews 
contained randomised controlled trials (RCT). Six reviews were restricted to only examining RCTs. 
The total number of participants included was 17,469 (17.8% male; 31.7% female; 50.4% unknown) 
with a mean age of 45.9 years and a mean age range of 8.3 years. Ten percent (n=1669/17469) had 
Relapsing-Remitting, 5.6% (1023/17469) had Progressive (Primary/secondary/unspecified) and 83 % 
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(13446/17469) were unknown. The average duration of MS was not clearly stated across reviews. In 
the majority (20/24, 83%) of reviews, the length of time of fatigue and its severity was unknown. A 
meta-analysis was conducted in six (6/24, 25 %) reviews. Duplicates of articles were included in the 
analysis as in some reviews the results were combined and presented as a concluding summary.  
Outcome measures were categorised into the following domains of MSRF; Fatigue Severity and 
Extent, Physical Fatigue (Effects on ADLs, Exercise, Hobbies), Mental Fatigue (Psychosocial, Social, 
Distress), Vitality, Prevalence/Pattern of Fatigue and Qualitative Fatigue Data. Outcome measures 
that analysed more than one domain were placed in both groups. This was to be aware of the reviews 
which included studies with outcome measures that covered many of the domains or vice versa. It 
highlighted areas of fatigue that were not covered and could be included in future research. 
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Figure 1 The PRISMA flow diagram (adapted from Moher et al., 2009) 
Grading Criteria of Analysis 
The AMSTAR score of the reviews is seen in Table 22. The mean scoring of the AMSTAR grading 
scale was 6.5 (SD=1.9: 95% CI=5.8-7.3). Three reviews were scored as low (0-4), 18 reviews were 
scored moderate (5-8) and 3 reviews were scored high (9-11). 
All pharmacological reviews (n=7) had “fair” grading of analysis (Created by the author; see 
supplementary file). Majority of reviews (71%; 5/7) had “fair” outcome measures with 50% of 
outcome measures having adequate validity and reliability and “fair” key domains (86%; 6/7) and 
analysing 3-4 key domains. Lee
5
 covered six key domains with included outcome measures.  Four 
reviews
243,24,25,-267
 had “poor” results with vague or unclear results with no statistics. No reviews had 
“good” results, this had an impact on the specificity of the synthesis undertaken within this overview. 
Six reviews scored “poor” in reporting risk of bias, this meant results were unclear, had not assessed 
risk of bias or included studies had a high risk of bias. Brown
287
 scored “poor” in the AMSTAR score.  
In non-pharmacological reviews, the majority had a “fair” grading apart from two reviews28,29 which 
were regarded as “poor”. Majority of reviews (84%; 16/19) had “fair” outcome measures with 50% of 
outcome measures having adequate validity and reliability and “fair” key domains (79%; 15/19)  with 
the outcome measures analysing 3-4 key domains. Two reviews
30,5
 covered six key domains with 
included outcome measures.  Five reviews had “poor” results with unclear or vague results and no 
statistics. Five reviews,
2,8,321-,32,343
 had “good” results with statistical analysis and meta-analysis. Eight 
reviews9,243,298,321,354-,35,36,378 scored “poor” and two reviews29,3028 scored “good” risk of bias. Two 
reviews
28,376
 scored “poor” in the AMSTAR score and three reviews310,3132,397 had “high” AMSTAR 
score. 
 
Table 2-Analysis of the Methodological Quality of the Reviews 
Review (First 
Author) 
Outcomes Key Domains 
(n= x/6) 
Risk of Bias AMSTAR (n = 
x/11) 
Branas34 Qualitative, Preferred treatment, MS-FS, 
FSS,RIV,VAS, FIEDL,DFE 
5 Unclear 7 
Brown27 FSS,EDSS,VAS,FAI, MFIS 3 N/A 2 
Lee5 VAS,MFIS,FSS, Epworth Sleep Scale, 
MSQOL,MFI, SF-63,FIS,DFE  
6 Mod/ Low 5 
Pucci23 EDSS,VAS,Preferred treatment, MS-FS, 
RIV,FSS,FIS  
4 High 6 
Taus24 Preferred treatment,VAS, 
EDSS,RIV,FSS,MS-FS 
4 High 6 
Tejani25 FSS,FIS  3 Unclear 8 
Tejani26 FSS,FIS,VAS,MFIS,SIP 3 Unclear 8 
Andreasen9 CFS,MFIS,FSS,MFI, qualitative 4 N/A 5 
Asano25 MFIS,FSS,MFI,VAS, FIS,FS,FAI  3 N/A 6 
Blikman8 MFIS,FSS,IPA, FIS,MSFS,SF-36  5 Mod /Low 7 
Branas34 Not included 5 Unclear 7 
Cramer31 MSQOL,MSIS,SF-36,FSS,MFIS,MFI  3 High 7 
Dalgas29 Unclear 0 Low 6 
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Heine32 FSS,MFIS,MFI,VAS,SF-36, 
MSQOL,FSMC,POMS   
4 Moderate 10 
Karpatkin36 (in 5 studies) ODI, FSS,FIS,FDI,MSIS  3 N/A 4 
Khan30 SF-36,VAS,MS-QOL, Fatigue Frequency, 
EDSS,FIM,MSIS,FIS,FSS 
6 Mod/ High 9 
Khan37 (5studies) MSIS,FSS,FIS,SF-36, MFIS  4 High 10 
Latimer-
Cheung2 
SF-36, POMS,MSQOL, FSS,MFIS  4 Mod/ Low 6 
Lee5 VAS,MFIS,FSS, Epworth Sleep 
Scale,SQOL,MFI, SF-63,FIS,DFE  
6 Mod/ Low 5 
Malcomson38 POMS, SF-36, MSIS, MSQOL 3 Low 6 
Pilutti33 FSS,MFIS,MSQOL,SF-36.POMS,MFI, SIP 4 Mod/ High 7 
Plow26 SF-36, FIS,MFIS  4 N/A 3 
Rietberg39 EDSS,SF-36,FSS, MSIS,FAMS,SIP,FIM  4 Mod 7 
Simpson40 SF-36  1 Mod/ High 7 
Steultjens11 FIS,SF-36  3 Mod 7 
Thomas10 MSQOL,SF-36, HRQOL,FAI,SIP,EDSS, 
MAFS  
4 Unclear 8 
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Review Description Number of 
Studies  
Types of 
Studies 
Methods Described (SALSA) AMSTAR 
Score 
Search Appraisal Synthesis Analysis 
Andreasen, 
2011
 
Systematic 
Review of the 
Literature 
23 articles 
(21 trials) 
RCT: 10 
CT: 3 
UC:8 
8 Databases None Narrative, Tabular, 
Qualitative 
Descriptive 5/11 
Asano, 2014
 
Review 25 RCT:25 4 Databases Effect Size  Narrative, 
Tabular 
Descriptive 6/11 
Blikman, 
2013
 
Systematic 
Review of RCTS 
and CCT 
6 RTC: 4 
CT:2 
4 Databases Risk of Bias using a Furlan et al 
quality criteria list  
Narrative, Tabular,  Meta-analysis using 
Forest Plots for 
Statistical 
Heterogeneity 
Descriptive. 
7/11 
Branas, 2000 Scoping Review 15  RTC: 9 
CT: 2 
UC: 4 
7 Databases, 1 
publication, 3 
websites and 
contacted experts 
Assessment of Validity was based 
on Jadad Scale. Cochrane Risk of 
Bias 
Narrative, Tabular Meta-analysis using 
RevMan 4.0.4 
software 
7/11 
Brown, 2010 Literature 
Review 
6 UC:6 2 Databases None Narrative, Tabular Descriptive 2/11 
Cramer, 2014 Systematic 
Review of RCTs, 
RCOT, CRT 
7 RCT:7 7 Databases, 2 
Journals 
Cochrane Risk of Bias Tabular, Narrative, Meta-analysis using 
review 
Manager 5 software.  
Hedges’s correction 
for small study 
samples, Statistical 
heterogeneity using 
the I2 statistics. Risk 
of Bias across 
studies. Review 
Manager software, 
sensitivity analysis. 
7/11 
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Dalgas, 2015 Systematic 
Review of RCTs 
15 RCT:15 8 Databases PRISMA, PICO, PEDro scoring Tabular, Narrative Meta-analysis using  
Meta-Analysis of 
Observational Studies 
in Epidemiology 
Framework, Forest 
Plot of the individual 
studies unable to be 
meta-analysed. 
6/11 
Heine, 2015 Cochrane 
Systematic 
Reviews of 
RCTs 
45 RCT:45 8 Databases Cochrane Risk of Bias, PEDro 
scale, Cochrane Handbook for 
Systematic Reviews of 
Interventions. Methodological 
quality of studies using the 
GRADEpro software. 
Tabular, Descriptive, 
Narrative 
Meta-analysis, Forest 
Plot of assessment of 
heterogeneity, 
Sensitivity analysis. 
Funnel Plots for 
assessing publication 
bias 
10/11 
Karpatkin, 
2014 
Systematic 
Literature search 
15 (14 trials) 
(3 on fatigue) 
UC:3 3 Databases None Descriptive, Tabular Descriptive 4/11 
Khan, 2007 Cochrane 
Systematic 
Review of RCT 
and CCT 
13 RCT:11 
CT:2 
7 databases, 
Authors, relevant 
journals, 
unpublished 
trials 
Cochrane Handbook for 
Systematic Reviews of 
Interventions. Review Manager 
software developed by the 
Cochrane Collaboration, 
Cochrane Risk of Bias 
Tabular, Descriptive, 
Narrative 
Sensitivity analysis, 
investigation of 
heterogeneity 
9/11 
Khan, 2015 Cochrane 
Systematic 
Review of RCT 
and CCT 
9 RCT:9 7 Databases, 
journals, ongoing 
and unpublished 
trials 
Methodological quality of studies 
using the GRADEpro software.  
Review Manager 5 software 
developed by Cochrane, 
Cochrane Risk of Bias 
Narrative, Descriptive Heterogeneity 
analysis, unit of 
analysis, sensitivity 
analysis (Grade) 
10/11 
Latimer-
Cheung, 2013 
Systematic 
Review of the 
54 (30 on 
fatigue) 
RCT:11 
CT:12 
7 Databases PEDro for study quality in RCTS 
and Downs and Blacks for 
Narrative, Descriptive, 
Tabular 
Cochrane Handbook 
for Systematic 
6/11 
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Literature NRCTs Reviews of 
Interventions for 
descriptive synthesis 
Lee, 2008 Systematic 
Review of the 
Literature 
15 RTC: 9 
CT:4 
UC:2 
12 Databases Quality of studies reviewed 
(unknown) 
Narrative, Tabular Descriptive 5/11 
Malcomson, 
2007 
Systematic 
Review of the 
Literature 
33 RCT:9 
CT: 16 
UC:8 
16 Databases Downs and Black Quality 
Checklist. 
Narrative, Descriptive Descriptive 6/11 
Pilutti, 2013 Quantitative 
synthesis of 
randomized 
controlled trials 
17 RTC: 17 4 Databases PEDro  Narrative Descriptive Meta-analysis of 
Observation Studies 
in Epidemiological 
framework. ESs for 
each study were 
entered into the 
Comprehensive 
Meta-Analysis 
software,  
Heterogeneity of the 
overall ES 
7/11 
Plow, 2013 Scoping Review 34 articles 
(27 
interventions) 
RTC:13 
CT:6 
UC:8 
3 Databases, 4 
journals 
None Tabular, Descriptive Descriptive 3/11 
Pucci, 2007 Cochrane 
Systematic 
Review of the 
Literature 
5 RCT:5 5 Databases, 4 
journals 
The scoring for allocation 
concealment, Jadad’s scale, 
Cochrane Risk of Bias 
Descriptive, Narrative Descriptive 6/11 
Rietberg, 
2005 
Cochrane 
Systematic 
Review of the 
Literature 
9 RCT:9 7 Databases, 1 
journal 
Methodological quality 
assessment (11 scoring system), 
kappa statistics Cochrane 
Methodological Quality of 
Tabular, Descriptive, 
Narrative 
Descriptive 7/11 
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Included Studies 
Simpson, 
2014 
Systematic 
Review of 
Evidence 
3 RCT:2 
CT:1 
7 Databases SPIO-study design, Cochranes 
Collaboration for Risk of Bias 
Tabular, Narrative Descriptive 7/11 
Steultjens, 
2003 
Cochrane 
Systematic 
Review 
3 RCT:1 
CT:1 
UC:1 
9 Databases, 
authors 
Methodological quality by list of 
Van Tulder List. Cochrane risk of 
bias 
Descriptive, 
Narrative, 
Tabular 
Descriptive. 
Standardised mean 
differences. Odds 
ratios, Sensitivity 
analysis 
7/11 
Taus, 2003 Cochrane 
Systematic 
Review 
4 RCT:4 1 Database, 4 
Journals 
Methodological Quality of the 
Cochrane Checklist 
Narrative Descriptive 6/11 
Tejani, 2010 Cochrane 
Systematic 
Review 
1 RCT:1 4 Databases, 4 
journals 
Cochrane Risk of Bias, Quality 
Checklist 
Tabular, Narrative Forest Plot of 
Heterogeneity 
analysis, Sensitivity 
Analysis 
8/11 
Tejani, 2012 Cochrane 
Systematic 
Review 
2 RCT:2 5 Databases Quality Checklist, Cochrane Risk 
of Bias,  
Descriptive, Tabular, 
Narrative 
Heterogeneity and 
descriptive analysis 
(Forest Plot) 
8/11 
Thomas, 
2006 
Cochrane 
Systematic 
Review 
17 RCT:17 19 Databases, 
trials in progress 
Cochrane Allocation 
Concealment 
Tabular, Descriptive, 
Narrative 
Data Extraction tool, 
Meta-analysis of 
mini-reviews, 
Homogeneity 
Analysis (Chi-
squared/Odds 
ratio/Mantel-
Haenszel) 
8/11 
 
Abbreviations: CT: Controlled Trial, RCT: Randomised Control Trial, UC: Uncontrolled Trial 
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ResultsTable 2 Grading criteria used to assess overall quality of the reviews 
Note: Abbreviations. CFS=Chandler’s fatigue scale, DFE= Diary of Fatigue Experience, EDSS= Expanded Disability 
Status Scale, FAI=Fatigue Assessment Instrument, FAMS=Functional Assessment of Multiple Sclerosis, FDI=Function and 
Disability Inventory, FIEDL= Fatigue Inventory of Effects on Daily Living, FIM= Functional Independence Measure,  
FIS=Fatigue Impact Scale, FSS=Fatigue Severity Scale, FSMC=Fatigue Scale for Motor and Cognitive Functions, 
HRQOL-MS=Health Related Quality of Life for Multiple Sclerosis, IPA, Impact on Participation and Autonomy, 
MAFS=Multidimensional Assessment of Fatigue Scale, MFI=Multidimensional Fatigue Inventory, MFIS=Modified Fatigue 
Impact Scale, MS-FS=Multiple Sclerosis Functional Score, MSQOL=Multiple Sclerosis Quality of Life, MSIS=Multiple 
Sclerosis Impact Scale, ODI= Oswestry disability index, POMS=Profile of Moods States, RIV= Rand Index of Vitality, 
SEP59=Multiple Sclerosis Quality Of Life scale, SF-36=Short Form-36 Vitality Subscale of the Short Form Health Survey, 
SIP=Sickness Impact Profile, SPFS=Subjective Perception of Fatigue Scale, VAS-Visual Analogue Scale. In Branas (2000) 
only pharmaceutical interventions included the relevant outcome measures. 
 
 
 
Tabulation and Translation of Findings of Interventions  
. In total Fifty-five pharmacological and non-pharmacological grouped interventions were found in 
this review. The results of the interventions are listed in Table 3 and 4. Below the outcome measures 
are categorised into the following domains of MSRF; Fatigue Severity and Extent, Physical Fatigue 
(Effects on ADLs, Exercise, Hobbies), Mental Fatigue (Psychosocial, Social, Distress), Vitality, 
Prevalence/Pattern of Fatigue and Qualitative Fatigue Data. Outcome measures that analysed more 
than one domain were placed in both groups. 
 
 
Pharmacological Interventions 
In total, seven reviews examined the pharmacological interventions available (see table 3):   
Summary and recommendation for pharmacological interventions 
Evidence is reported by drug type below: 
 (a) Amantadine was identified as not significantly affecting fatigue in 66% (10/15) of the included 
reviewsstudies. Where significant change was identified (4/15) this was identified within the 
following domains: Mental Fatigue (4/4; 100%), Physical Fatigue (4/4; 100%), Fatigue Severity and 
Extent (4/4; 100%), Vitality (4/4; 100%) and Prevalence and Pattern (1/4; 25%) 
 (b) Pemoline had conflicting results from two reviews with the majority ofmost studies (3/4; 75%) 
concluded insignificant effects on MSRF. The included key domains were Mental Fatigue (2/2; 
100%), Physical Fatigue (2/2; 100%), Fatigue Severity and Extent (2/2; 100%), Vitality (2/2; 100%) 
and Prevalence and Pattern (1/2; 50%). 
 (c) Modafinil was identified to have significant improvement on fatigue in 751 % of studies (65/87) 
in 2 reviews. The included key domains were Fatigue Severity and Extent (2/2; 100%), Mental 
Fatigue (2/2; 100%), Physical Fatigue (2/2; 100%), Prevalence and Pattern (1/2; 50%) and Vitality 
(1/2; 50%). 
 (d) Prokarin was only considered within one pilot study
5
 where a significant improvement in MSRF 
was reported. The key domains covered in the single study were unknown.  
(e) Carnitine was identified to have inconclusive insignificant results on MSRF in the two included 
reviews. The included domains were Fatigue Severity and Extent (2/2; 100%), Physical Fatigue (2/2; 
100%) and Mental Fatigue (2/2; 100%). 
 (f) Pemoline combined with aspirin found an improvement in MSRF in one study in Lee, et al.,
5
 but 
the key domains of were not detailed.    
 15 
 
                                                                                                                                                                                                                                                                                                                                     
There are currently no reviews assessing the effects of Aminopyridine
3,4 
Diaminopyridine, Interferon 
Beta 1b and antidepressants on fatigue improvement in MS5,7. This could be an area in future research 
that could be investigated. 
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Intervention Review 
(First 
Author) 
Results of Within Reviews Summary of Significant 
results and side effects 
 
Asano 365 Significant Results: None found  
 
Non-Significant Results: ES for Amantadine−0.59 (95%CI: −1.26 to 0.06). 5 studies* found no significant effects  
 
Side Effects Identified: None reported  
A
m
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Branas354 Significant Results: Four studies** (n=236) concluded improvement in MS fatigue. One did not define fatigue symptoms and had limited 
information.  Another examined fatigue effects with VAS (p>0.05) and others used MS-FS (P=0.04), FSS (P=0.33) and Daily Rating Point Scale 
(p=0.58).  
Significant Results: 3 
reviews34,24,5 reported 
significant fatigue 
improvements.  However, 
4/9 of the studies34,24 
contained data of limited 
quality. Therefore, 5/15 
studies reported fatigue 
improvement with 
amantadine 
 
 
 
Side effects: Average of 
40% participants in 4 studies 
reported adverse side effects. 
Non-Significant Results:  The clinical significance examined in one study looking at activities of daily living. A validated outcome measure not 
used so results were inconclusive. 
Side Effects Identified: 20-60% participants reported side effects but no significant difference between studies against placebo. Side effects 
included sleep disturbances, palpations, insomnia, headaches, nausea and constipation. 
Taus254 Significant Results: In 3 studies**, 30.3% of respondents preferred amantadine (n=183). One study had 60% of respondents preferred 
amantadine but these were the only responders (total n=10). 
Non-Significant Rresults: Subjective improvement in fatigue in the final study** but results expressed as patient preference so data could not 
be summarised.   
Side Effects Identified: 40% of participants compared to 35.5% placebo reported side effects (hallucinations, nausea, hyperactivity, anxiety and 
insomnia). Less than 10% of participants dropped out because of adverse effects. 
Pucci243 Significant Results: None 
Non-Significant results: Subjective improvement in fatigue with amantadine in 5 studies ** (n=190) but insufficient data to justify. 
Side Effects Identified: Side effects reported in 40% of participants in one study with a dropout rate of 28% and another over 40% of 
participants had side effects (hallucinations, nausea, hyperactivity, anxiety and insomnia). 
Lee5 Significant Results: Two studies (n=110One study)* concluded improvement in MS fatigue.  One study found fatigue improved (p<0.01) in 
115 out of 165 participants.  
Non-Significant Rresults: The remaining study examined the neurophysiological measures of fatigue compared against a placebo, amantadine 
and pemoline but no significant differences found. 
Side Effects Identified: All studies reported adverse effects. Twenty one percent (n=165) of participants reported insomnia with taking 
amantadine. 
P
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Branas354 Significant Results: None Significant Results: 
Subjective fatigue 
improvement in 1 study in 
one review5 
Side effects: 3/4 studies 
Non-Significant Rresults: Two studies* found no improvement in fatigue with Pemoline against a placebo. None examined clinical effects of 
pemoline on quality of life. One found no significant difference between pemoline and placebo (p>0.05) and the other had negative effects on 
FSS outcome measure and positive on the MS-FS outcome measure but neither were significant (p=0.845 and p=0.394). 
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Side Effects Identified: Both studies reported adverse effects with pemoline. In one study the number of participants with side effects was 
unknown. In the other >25% reported side effects (irritability, insomnia, nausea and anorexia). 
reported adverse side effects. 
25% participants reported 
effects in one study and 
another 26% dropped out 
because of effects 
Lee5 Significant Results: ½ 1 /2studies (n=46) had 46.3% of participants achieving “excellent or good” fatigue relief with pemoline compared to 
19.5% with placebo (p=0.06). 
Non-Significant Rresults: 1/2 studies* (n=126) found no significant changes in neurophysiological measures with placebo, pemoline or 
amantadine. 
Side Effects Identified: In one study (n=46) 26% of patients dropped out of the study due to adverse side effects (anorexia, irritability and 
insomnia). Side effects not reported in the other study. 
M
o
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Asano365 Significant Results: 1 study* found a significant effect on MSRF.  Significant Results: 65/8 7 
studies found significant 
fatigue improvement with 
Modafinil 
 
 
 
Side effects: Reported in 1 
reviews 273 studies reported 
adverse effects and in 2 
studies  therestudies there 
was a 5-29% dropout rate 
because of this. 
Non-Significant Results: ES was 0.55 (95%CI: −0.06 to 1.16). 1/2 studies had no significant effect on MSRF 
Side Effects Identified: None reported 
Lee5 Significant Results: 1/2 studies* (n=72/187) found that FSS scores decreased (0<0.001) and MFIS (P<0.001) and VAS (p=0.003).  
Non-Significant Rresults: One study (n=115) had improvements in the MFIS with modafinil and the placebo (52.3 +- 18.5 versus 49.2+-16.6) 
but no significant differences between treatments (p=0.27).   Both studies are reviewed by Brown12. 
Side Effects Identified: None reported 
Brown287 Significant Results: Five studies* (n=308). Short-term efficacy (12 weeks) in fatigue improvement (22% reduction in symptoms seen in 4 
uncontrolled studies of patient taking 200mg or less of modafinil). One study (n=55) found an improvement in the FSS (P<0.001) and in the 
Epworth Sleepiness Scale (P<0.001) compared to baseline. One study found 50% of participants (n=33) had improvement in VAS score 
compared to baseline. One study examined MS (n=17) with other neurological conditions found a significant improvement in FSS (P=0.006) but 
not in the Epworth Sleep Score(p<0.05). Another study (n=72) found FSS scores decreased (p<0.001) and in MFIS (P<0.001) and VAS 
(p=0.003). One study (n=115) had improvements in the MFIS with modafinil and the placebo (52.3 +- 18.5 versus 49.2+-16.6) but no significant 
differences between treatments (p=0.27).  The fifth study (n=21) found lower FSS than baseline results when comparing against a placebo 
(p=0.023).  
Non-Significant Rresults: None 
Side Effects Identified: In one study (n=55) 3 patients dropped out due to adverse effects (nervousness and increased vertigo).  In another 
(n=17) 5 patients dropped out due to side effects (headache, excitability and hypertension=seen in all neurological patients in the study). In one 
study (n=72) adverse effects reported were headache, nausea and asthenia). 
P
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Lee5 Significant Results: Improvement in MS fatigue was seen in a pilot study (n=22) with Prokarin. MFIS mean was significantly different from the 
placebo (p=0.02).  
Significant Results: Fatigue 
improvement seen in 1 pilot 
study 
Side effects: Not reported 
Non-Significant Rresults: None 
Side Effects Identified: Adverse effects not recorded 
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Tejani265 Significant Results: None Significant Results: None 
 
Side effects: Not reported 
Non-Significant rResults: No studies* found clear results on Carnitine when compared with amantadine due to an adverse event resulting in 18 
patients dropping out (n=36)  (Relative Risk Ratio 0.20. 95%CI 
Side Effects Identified: Adverse effects not recorded 
Tejani276 Significant Results: None 
Non-Significant resultsResults No studies* found clear results on Carnitine when compared with amantadine. Adverse event resulted in 18 
patients dropping out (n=36) (Relative Risk Ratio=0.20.95%CI). Review analysed the same study as Tejani15 as there were no other finished 
trials at the time of analysis. 
Side Effects Identified: Adverse effects not recorded  
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Table 3 Pharmacological interventions and supporting evidence form review 
Note: * indicates review was deemed poor quality through critical appraisal process.: Abbreviations. CFS=Chandler’s fatigue scale, DFE= 
Diary of Fatigue Experience, EDSS= Expanded Disability Status Scale, FAI=Fatigue Assessment Instrument, FAMS=Functional 
Assessment of Multiple Sclerosis, FDI=Function and Disability Inventory, FIEDL= Fatigue Inventory of Effects on Daily Living, FIM= 
Functional Independence Measure,  FIS=Fatigue Impact Scale, FSS=Fatigue Severity Scale, FSMC=Fatigue Scale for Motor and 
Cognitive Functions, HRQOL-MS=Health Related Quality of Life for Multiple Sclerosis, IPA, Impact on Participation and Autonomy, 
MAFS=Multidimensional Assessment of Fatigue Scale, MFI=Multidimensional Fatigue Inventory, MFIS=Modified Fatigue Impact Scale, 
MS-FS=Multiple Sclerosis Functional Score, MSQOL=Multiple Sclerosis Quality of Life, MSIS=Multiple Sclerosis Impact Scale, ODI= 
Oswestry disability index, POMS=Profile of Moods States, RIV= Rand Index of Vitality, SEP59=Multiple Sclerosis Quality Of Life scale, 
SF-36=Short Form-36 Vitality Subscale of the Short Form Health Survey, SIP=Sickness Impact Profile, SPFS=Subjective Perception of 
Fatigue Scale, VAS-Visual Analogue Scale. *1-3 duplicate articles within findings, **4-6 duplicate articles within findings, *** 7+ articles 
 
 
 
 
 
Non-Pharmacological Interventions 
Forty-six non-pharmacological interventions were found from the reviews. Table 4 provides a 
summary of this evidence.  
 
Summary and recommendation for non-pharmacological interventions 
Evidence is reported by intervention type below: Many reviews grouped exercise interventions to 
conclude an overall outcome. Individual exercises were not examined due to an inability to compare 
because of the heterogeneity of the data. The subtype of exercise was not examined in Rietberg
4039
, 
but an overall improvement in MS fatigue was seen with exercise interventions although statistical 
data was not included. The key domains covered in the review were Physical Fatigue, Vitality, 
Fatigue Severity and Extent and Mental Fatigue. 
 (a) Endurance training was identified to have a significant improvement in MS in four reviews 
(19/374 studies, 7951%). In particular Heine
3322
 conducted a meta-analysis of 12 studies and a 
significant effect on fatigue was concluded (SMD-0.43, 95% CI -0.69 to -0.17; P < 0.01). The 
included key domains were Mental Fatigue (3/4; 75%), Physical Fatigue (3/4; 75%), Fatigue Severity 
and Extent (3/4; 75%) and Vitality (2/4; 50%). 
 (b) Resistance training was identified to have a significant improvement on MSRF in six reviews 
(136/1930; 5368%). The included key domains were Vitality (3/6; 50%), Mental Fatigue (5/6; 83%), 
Physical Fatigue (5/6; 83%) and Fatigue Severity and Extent (5/6; 83%). 
 (c) Aerobic training identified an improvement on MSRF in three reviews (116/106; 680%). The key 
domains were Mental Fatigue (3/3; 100%), Physical Fatigue (3/3; 100%), Fatigue Severity and Extent 
(3/3; 100%) and Vitality (3/3; 100%). Malcomson
38 
was not considered in the results as fatigue was 
not examined as an outcome.  
(d) Combined training (multiple exercise types used) identified an improvement on MS fatigue in five 
reviews (1320/23/25; 8752%). The included key domains were Fatigue Severity and Extent (4/5; 
80%), Mental Fatigue (4/5; 80%), Physical Fatigue (4/5; 80%) and Vitality (3/5; 60%). 
  (e) Yoga identified a significant reduction on MSRF in seven reviews (18/22; 81%). The included 
key domains were Fatigue Severity and Extent (6/7; 86%), Mental Fatigue (6/7; 86%), Physical 
Fatigue (6/7; 86%), Prevalence and Pattern (1/7; 14%) and Vitality (4/7; 57%).  
(f) CBT and other behavioural interventions (mindfulness and tele-rehabilitation) identified an 
improvement on MS fatigue in 5 reviews (5/1810/22; 4527%). The key domains were Mental Fatigue 
Comment [AS4]: Delete this? 
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(3/5; 60%), Physical Fatigue (3/5; 60%), Vitality (4/5; 80%) and Fatigue Severity and Extent (2/5; 
40%). 
 (g) Energy conservation and fatigue programs identified an improvement on MS fatigue in six 
reviews (262/269; 76100%). The key domains were Mental Fatigue (6/6; 100%), Physical Fatigue 
(6/6; 100%), Vitality (5/6; 83%) Prevalence and Pattern (1/6; 17%), and Impact on Participant and 
Autonomy (1/6; 17%) and Fatigue Severity and Extent (4/6; 67%). (g) MDR identified a significant 
improvement on MS fatigue in three reviews (3/6; 50%). The key domains were Mental Fatigue (3/3; 
100%), Physical Fatigue (3/3; 100%), Fatigue Severity and Extent (3/3; 100%), Prevalence and 
Pattern (1/3; 33%) and Vitality (2/3; 67%). 
(h) Acupuncture identified an improvement on MS fatigue in one review. The key domains were 
Mental Fatigue, Fatigue Severity and Extent and Physical Fatigue. 
 
 
 
 
 
 
 
Comment [AS5]: Needed? 
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Intervention Review (First 
Author) 
Results of Within Reviews Summary of Significant 
results  
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Branas354 Significant Results: None Significant Results: 
19/374 studies concluded 
an significant 
improvement on MSRF 
with endurance training 
 
 
 
 
Non-Significant results:1 study but the results are not discussed. 
Andreasen9 Significant Results: 54/117 studies* (n=173) concluded significant improvements in fatigue. Studies examined ergometer bicycling 
(n=8 FSS p=0.058 pre and post intervention)(intervention) (n=36  MFIS p<0.05)(n=14 p=<0.05 when compared against active 
control)(n=15 p<0.01).  
Non-Significant results: 63/117 studies* concluded no significant effect. 
Heine332 Significant Results: 17 studies* used endurance interventions and 2/7 concluded a significant effect. 11 studies used in meta-analysis 
(n=156 participants versus n=110 control) and a significant effect concluded (SMD=-0.43, 95% CI,-CI, -0.69 to -0.17, p<0.01). 
Non-Significant results: 5/7 studies* included in Andreaseon89 concluded no effect on fatigue. 
Dalgas3029* Significant Results: 3/9 studies* previously included in Andreasen89 and Heine3320. Statistical data not included but 4 studies reported 
an improvement in fatigue (1 temporary and 1 incomplete data). 
Non-Significant results: 4/9* concluded no effect. 
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Andreasen9 Significant Results: 3/7 studies**s (randomised trials) contained statistical data (n=31). In one study 7/8 participants reported 
decreased fatigue and 2 studies found significant effects on fatigue  (fatigue (p<0.05 and p<0.04). 
Significant Results: 
13/16/3019 studies 
concluded a significant 
improvement on MSRF 
with resistance training 
 
 
 
 
 
 
Non-Significant results: None4 studies did not contain statistical information. 
Latimer-cheung2 Significant Results: Levels of evidence discussed in the aerobic training section. A study (level 1 evidence) concluded significant 
improvement in general fatigue with a 12 week12-week program. 3 studies** (level 4 evidence) reported decreased mental and 
physical fatigue after a 8-10 week program. 
Non-Significant results: None 
 
Pilutti343 Significant Results: 3 studies** listed as solely resistance training. Beneficial effect on MS fatigue concluded (0.42(-0.26 to 0.96)) 
(0.48(N/A)) (0.09(N/A)). 
Non-Significant results: Resistance trainings studies wereas unclear. 
Dalgas3029* Significant Results: 2 studies** examining the effects of resistance training (n=34). 1 study in Andreasen98. Statistical data not 
included but one study showed weak but significant improvement in MS fatigue. 
Non-Significant results: None 
 
Asano365 Significant Results: 1 6 study** had significant positive effect on MSRFies (ES 0.81 CI=0.08–1.15)had a mean ES 0.63 (0.31-0.88) 
compared to control ES 0.16(-0.003-0.79). When applying 95%CI 1 studies had significant results. 
Non-Significant results: 2 studies had no significant effect (ES 0.24 CI=1.15–0.64; ES 0.20 CI=0.60–1.02)5/6 studies had non-
significant effects when compared against the control 
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Heine323 Significant Results: 2/8 trials**  included in Andreasen8 and Dalgas19. 4 trials** in the meta-analysis (n=146 participants versus 61 
control) showed a heterogeneous (p=0.02) non-significant effect versus a control. The standard mean deviation (SMD) combined with 
SMD of the best powered trial concluded resistance training could impact fatigue by 0.3 points on the FSS (95% CI-6.3 to 6.9) or 0.5 
points on the MFIS (95%CI 11.2-12.3). 
Non-Significant Rresults: None 
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Branas354 Significant Results: 1 RCT* concluded moderate aerobic exercise might be beneficial in fatigue management.  None Significant Results: 
116/160 studies found a 
significant improvement 
on MS fatigue with 
aerobic training 
 
 
 
 
Non-Significant Rresults: 1 RCT concluded moderate aerobic exercise might be beneficial in fatigue management.None 
Pilutti343 Significant Results:. One study* found significant benefit of aerobic exercise on fatigue (ES=1.27(0.29-2.25). 
Non-Significant Rresults: 5/6 studies* had the lowest effect size of all studies examined (ES -0.26) but the studies were not 
individually listed so cannot be examined. Mixed conclusions on effects of training so 5 of the studies had insignificant results 
Latimer-Cheung2 Significant Results: 13 8 studies* examined fatigue changes in aerobic training. The included studies were assessed for their “level of 
evidence” (levels 1-4). (Level 1= RCT studies with PEDRO score >6.) 53 RTCs (level 1 evidence) reported significant improvement in 
fatigue symptoms but not specific to MS fatigue. 31 study (level 4 evidence) concluded significant improvements in fatigue with a 8 
week aerobic program.  
Non-Significant Rresults: Statistical data pre and post intervention not included for fatigue. The 9/13studies concluded no significant 
changes in fatigue.None 
Asano36
 
Significant Results: ES for ranged from −0.24 (95%CI: −1.15 to 0.64) to 2.05 (95%CI: 1.00–3.11). After taking 95%CI into 
consideration, only one aerobic study* presented a significant intervention effect 
Non-Significant Results: None  
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Andreasen9 Significant Results: 2/5 studies* (total n=97) found a significant improvement in fatigue with combined training (n=9 p=0.01 Pre/post 
46+-6.3/39.4+-3.4) (n=12 p=0.02). 1 study recording qualitative data found combined training correlated with improvements in fatigue 
(n=10).  
Significant Results: 
2013/235 studies found a 
significant improvement 
on MS fatigue with 
combined training  
 
 
 
Non-Significant Rresults: The final 2/5 studies found no significant effect on fatigue. 
Pilutti343 Significant Results: None 
Non-Significant Rresults: Unclear which studies had mixed modalities of training. Inconsistency between the results and effect of 
combined training on fatigue inconclusive. 
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Latimer-Cheung2 Significant Results: 5 studies* reported significant changes in fatigue with a combined training program. 2 studies contained level 1 
evidence and 3 contained level 4 evidence. Levels of evidence are discussed in the aerobic training section. 
Non-Significant Rresults: None 
Dalgas3029* Significant Results: None 
Non-Significant Rresults: 2 studies (n=32) found no improvements in fatigue or depressive symptoms.  Statistical data was not 
included. 
Heine332 Significant Results: 13 studies* had endurance and power aspects. 6 studies (n=319 participants versus 176 control) included in meta-
analysis. Significant effect on fatigue with combined training (SMD-0.73, 95%CI-1.23 to -0.23 P<0.01). The SMD combined with SD 
of the best powered trial and found fatigue can improve to -7.1points on FSS (95%CI-11.9 to -2.2) and on the MFIS (95% CI-21.3 to-
4.0). 
Non-Significant Rresults: None 
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Lee5 Significant Results: 1 study*** concluded some benefit on fatigue. Statistical data was not available Significant Results: 
18/22 studies reported. 2 
additional studies 
reported some benefit 
with yoga but the details 
were not clear so marked 
as insignificant.  
 
 
 
 
Non-Significant Rresults: None 
Pilutti343 Significant Results: 2 studies*** found significant effect on fatigue. Average effect size 1.27(1.12-1.42) and 0.20(-0.20-0.62). 
Non-Significant Rresults: None 
Latimer-Cheung2 Significant Results: 1 study*** concluded some benefit on fatigue. Statistical data not available 
Non-Significant results: None 
Cramer321 Significant Results: Meta-analysis (7 studies*** n=670) concluded that yoga improved short-term fatigue compared to usual 
treatment (SMD=-0.52.95%CI. P=0.06). 
Non-Significant Rresults: None 
Heine332 Significant Results: 7 studies*** investigated the effects of yoga on fatigue. 1 studies examined by Dalgas19 and 5 were included in 
Cramer18. The results combined into “other training”. The mean fatigue outcome ES was 0.54 standard deviations lower (0.79 to 0.29) 
suggesting that yoga has beneficial effects on fatigue. 
Non-Significant Rresults: None 
Dalgas3029* Significant Results: 2 studies*** found no effect of yoga on fatigue. Statistical data not available.  
Non-Significant Rresults: None 
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Asano365 Significant Results: 2 studies mean ES of 0.535 compared to control 0.6. With 95% CI no studies were statistically significant None. 
Non-Significant Rresults: 2 studies*** mean ES of 0.535 compared to control 0.6. With 95% CI no studies were statistically 
significant None 
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Steultjens11Steultjen
s12 
Significant Results: None Significant Results: 
105/2218 studies 
reported fatigue 
improvement with 
behavioural interventions 
 
 
 
 
Non-Significant Rresults:esults:  Inconclusive effects with counselling due to poor methodological quality.No significant statistical 
data between counselling and the control group 
Malcomson388 Significant Results: 5 studies. 3 studies* found telephone administered CBT led to a significant reduction in depression (p= 0.02) 
(0.04), another study found depression levels were significantly reduced group using activity scheduling and cognitive techniques 
(p<0.01). A third study found CBT increased vitality (p=0.04).  Improvement in depression with CBT (p=0.004) but fatigue not an 
outcome measure. 
Non-Significant Rresults:  NoneNone.  
Simpson4140 Significant Results: Effects of mindful breathing and movement in 3 studies* (n=187). One found significant improvements in fatigue 
at 3 and up to 6 months (MFIS. P=0.41) (MFIS. p=0.035). 2/3 studies had significant improvements in p values (p>0.05 and p=0.035). 
Non-Significant Rresults: None 
Asano365 Significant Results: 2/4 studies* found significant improvement in fatigue 1=Mindfulness (ES=0.38), 2= CBT (ES=1.08, 2.99) and 
1=relaxation (ES=1.79). 
Non-Significant Rresults: None2/4 studies found no significant improvement in fatigue. 
Khan387 Significant Results: None 
Non-Significant Rresults:  Inconclusive effects of tele-rehabiliationrehabilitation on fatigue due to the large bias (9 studies) 
Plow28 
Significant Results: 2 studies* found statistically significant improvements in depression with CBT. However, this data was not 
included. 
Non-Significant Results: None  
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Steultjens4011 Significant Results: None1/2 studies* statistically significant decrease of impact of fatigue (effect size -0.75; 95% confidence interval 
-1.42 to 0.07). The other study found significant difference (0.01) on MSRF 
Significant Results: 
22/26/2629 studies 
reported improvement in 
MS fatigue with fatigue 
management 
interventions 
 
 
 
 
Non-Significant Rresults: Inconclusive effects of ECT on fatigue due to limited evidence available.None 
Thomas10 Significant Results: None 
Non-Significant Rresults:  Inconclusive effects on fatigue due to the small sample size of studies and not using fatigue as a primary 
outcome measure. 
Lee5 Significant Results:  2 studies*. 1 study found significant positive results on MSRF (<0.01). The other study found significant positive 
effect on MSRF with energy conservation (p<0.01)None  
Non-Significant results:  Inconclusive effects of ECT on fatigue due to limited evidence availableNone. 
Plow298* Significant Results: 12 studies examined effects of fatigue management programs on fatigue. Statistical data was not included. 
Improvement in symptomatic fatigue reported. 
Non-Significant results: None 
Blikman8 Significant Results: 6 studies in total with 2 included in the meta-analysis. Meta-analysis concluded improvement in fatigue when 
ECT compared against no treatment (Fatigue Impact Scale (Cognitive: MD=2.91.95% CI), (Physical: MD=-2.99. 95% CI) and 
(Psychosocial: MD=-6.05. 95% Confidence Interval). 
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Non-Significant Rresults: None 
Asano365 Significant Results: 4 /8 studies had statistically significant results on fatigue with ECT (ES=0.53-0.84). 
Non-Significant Rresults: None 
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Branas354 Significant Results: None Significant Results: 3/66 
studies reported 
improvement in MS 
fatigue with MDT 
interventions 
 
 
 
 
Non-Significant results: Inconclusive due to limited supporting evidence 
Khan380 Significant Results: Significant improvement in disability with MDR (3 studies (n=217))  
Non-Significant Rresults:  Limited evidence for symptom improvement in OP and HR treatments (total of 2 studies n=302). 
Heterogeneous studies 
Asano365 Significant Results: None 
Non-Significant Rresults:  Inconclusive due to the methodological quality and the limited effect size of 1the 2 studyies. 
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Karpatkin376* Significant Results:  3 studies (n=7) but one study contained subjective qualitative reports of increase in energy levels. One study 25% 
of patients (n=20) had a decreased FSS score to below 30 after treatment. The mean reduction was 20.6 +-7.2. In the final study, the 
mean ODI score reduced pre and post treatment (pre: 41.16+-3.72)(post:33.59+-5.14). 
Significant Results:  
Improvement on MS 
fatigue in one review. 
Note the review critiqued 
the poor methodological 
quality of the included 
studies Non-Significant Rresults: None 
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Table 4 Non-pharmacological interventions and supporting evidence form review 
 
Note: * indicates review was deemed poor quality through critical appraisal process. Abbreviations. CFS=Chandler’s fatigue scale, DFE= 
Diary of Fatigue Experience, EDSS= Expanded Disability Status Scale, FAI=Fatigue Assessment Instrument, FAMS=Functional 
Assessment of Multiple Sclerosis, FDI=Function and Disability Inventory, FIEDL= Fatigue Inventory of Effects on Daily Living, FIM= 
Functional Independence Measure,  FIS=Fatigue Impact Scale, FSS=Fatigue Severity Scale, FSMC=Fatigue Scale for Motor and 
Cognitive Functions, HRQOL-MS=Health Related Quality of Life for Multiple Sclerosis, IPA, Impact on Participation and Autonomy, 
MAFS=Multidimensional Assessment of Fatigue Scale, MFI=Multidimensional Fatigue Inventory, MFIS=Modified Fatigue Impact Scale, 
MS-FS=Multiple Sclerosis Functional Score, MSQOL=Multiple Sclerosis Quality of Life, MSIS=Multiple Sclerosis Impact Scale, ODI= 
Oswestry disability index, POMS=Profile of Moods States, RIV= Rand Index of Vitality, SEP59=Multiple Sclerosis Quality Of Life scale, 
SF-36=Short Form-36 Vitality Subscale of the Short Form Health Survey, SIP=Sickness Impact Profile, SPFS=Subjective Perception of 
Fatigue Scale, VAS-Visual Analogue Scale. . *1-3 duplicate articles within findings, **4-6 duplicate articles within findings, *** 7+ articles 
 
 
Discussion  
To the best of the author’s knowledge this is the first review of reviews to consider and include the 
current review evidence. Given the synthesis and evidence from the results this review is able to make 
recommendations of the impact from specific pharmacological and non-pharmacological interventions 
on MSRF.  
Clinical aim: to provide up-to-date evidence-based recommendations for the treatment of MS related 
fatigueMSRF. 
Scientific aim: To prioritise topics for future randomised clinical trials with sufficient power. 
The cCriteria for the concluding/recommendation statements that related to the confidence of 
evidence statements combined the following factors; the methodological quality of reviews, evidence 
of risk of bias within supporting studies, and total number of studies (excluding duplications) 
supporting the research and the number of supporting studies for the intervention.. Studies were rated 
as having no evidence to support a recommendation or were assigned one of three confidence related 
statements including: (1) ‘wWith ‘caution’(< 50% of studies had supporting evidence with 1 or less 
studies with high methodological quality), (2) ‘“with moderate confidence’” (>50% of studies and 2 
studies with high methodological quality) and (3) ‘“with high confidence’” (>75% of studies and 3 or 
more studies with high methodological quality). Considerations were made for the risk of bias, 
duplications and amount of current supporting studies. 
Discussion of Pharmacological Evidence  
No pharmacological studies contained strong evidence for their effectiveness in improving MSRF. 
Recommended for individual medications are examined below; 
Amantadine 
The guidelines for RCP412 and NICE4 were examined. The NICE guidelines did not identify 
supporting evidence for its recommendation of amantadine and the RCP
421
contained four RCTs, one 
randomised crossover trial and one CCT which supported the use of amantadine. Sixty-six percent of 
reviews included in this study (n=10/15) identified no significant improvement on MSRF.  However, 
6/11 studies were identified as duplicates and a total of 6 duplications of studies from the reviews 
were included (11 studies in total). tThe significant results from one study was included in 4 of the 
reviews. This lowers the power of the studies and accuracy of the results. Further, because of the high 
prevalence of side effects from Amantadine (20-60% of participants across studies) we have 
concluded that Amantadine should be considered “with caution”. This conclusion is supported by a 
recent review that identifies no positive benefits from Amantadine on MSRF, however current this 
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evidence is underpowered and of a short duration
7
. Furthermore, another review43 can only conclude 
amantadine has a modest effect on MSRF calling for larger clinical trials to support its 
recommendation in the NICE guidelines for MSRF. 
Prokarin 
The recommendation of Prokarin by the MS Society UK
42 however the to the best of the authors 
knowledge only one clinical trials existsexist.  Within the current  existing evidence, only one review5 
identified a single study using Prokarin in MSRF. No duplications were found. A statistical 
improvement was identified but the study was underpowered and had methodological shortcomings. 
Given this the current, the  review is not able to give a recommendation relating Prokarin to MSRF  
until further research is conducted.  
Modafinil 
A total of 751% (n=65/87) of studies in two three reviews
5,278,36
 found significant improvements in 
MSRF. Only two duplications were found between reviews (7 studies in total). However, another 
review43 found weak evidence supporting the use of Modafinil in MSRF and the NICE guidelines do 
not currently support the use of this drug for MSRF.  Thus, the current review can recommend 
Modafinil with “caution” but calls for larger clinical studies to be conducted.  
 
Other medications not currently recommended 
Six drugs (Pemoline, Carnitine, Aspirin, Aminopyridine, 3,4 Diaminopyridine, Interferon Beta 1b) 
and anti-depressants were considered.  
Pemoline 
The RCP
412
 recommends Pemoline for MSRF management, however Tur
7
 identifies negative results 
and notes the withdrawal of the drug for other conditions. We identified that 75% (n=3/4) of studies 
found Pemoline had no significant effect on MSRF in 2 reviews
354,5
. However there was a duplication 
between the reviews reducing the power of the results (3 studies in total). Thus, the current evidence 
we suggests the evidence should be considered ‘with caution’ that Pemoline has limited or no effect 
on MSRF. with “some confidencewith caution” that Pemoline has limited or no effect on MSRF.  
Carnitine 
Tejani
265,267
 were inconclusivehadidentified insignificant results oin the effect of carnitine on MSRF 
with 1 duplication found between reviews. , Tur
7
 found 2 experimental studies that identified some 
beneficial effect however, due to the both studies being underpowered having a small sample size thus 
reducing its power and a lack of a placebo in one. Tejani 
27 
concluded that the use of carnitine in 
clinical practice cannot be recommended as its effects on fatigue is unknown.  fFurther  research iin 
this area cannot be advised due to a lack of supporting evidence.s required. We cannot recommend 
Carnitine currently due to no supporting evidence.   
Medications with little or no supporting evidence 
Only one study in a past review
5
 considered Aspirin, this study identified a significant improvement 
on MSRF, however due to the limited evidence no recommendation can be made. Currently there are 
no reviews available to discuss the effectiveness of Aminopyridine, 3,4 Diaminopyridine, Interferon 
Beta 1b and antidepressants in MSRF management. 
 
Discussion of Non-Ppharmacological Evidence  
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The recommended interventions are discussed below; 
EducationEnergy Conservation and Fatigue Management Programs 
Tur
7
 along with NICE guidelines
4
 also recommend education programs for MSRF. The current review 
identified a total of 76100%26 (n=19/22)  studies across 6 reviews found an improvement in MSRF 
with either energy conservation or fatigue management programs. Nevertheless, duplications of 
studies were found resulting in only 14 studies. On the other hand, two systematic reviews7,43 along 
with NICE guidelines
4
 also recommend energy conservation or fatigue management programs for 
MSRF.  ThusThus, both programs are recommended with ‘“high confidence’” as effective for 
management of MSRF.  
 
 
Multidisciplinary (MDT) Interventions 
MDT interventions are recommended by NICE guidelines4 involving both physical and psychological 
treatments. Other review evidence7,434 identified improvements from complex interventions involving 
several techniques like exercise and energy effectiveness techniques. A total of 50% (n=3/66) of 
studies found a significant improvement in MSRF. Given this it is stated ‘with “caution’” that MDT 
interventions may be beneficial in fatigue improvement.  
Psycho-behavioural interventions 
CBT and mindfulness are recommended by NICE guidelines
4 
for MSRF management. This is 
supported by other review evidence
4435
. A meta-analysis of one review
46
 found CBT interventions 
were more superior in reducing fatigue severity (-0.60:95% CI) compared to non-CBT interventions (-
0.20: 95% CI). Only However, in this review of reviews; 2745% (n=5/1810/22) of studies found a 
significant improvement on fatigue with psycho-behavioural interventions. However, duplications of 
these studies were found giving a total of 11 studies affecting the accuracy of this data. A meta-
analysis by Van den Akker46 found a moderately positive short-term effect with CBT in MSRF. Given 
this we recommend generic psycho-behavioural interventions ‘with “cautionmoderate confidence’”.  
FFurther research with higher quality studies should be conducted in order toto investigate the 
potentially positive effects of CBT.. 
Exercise interventions 
A large number ofMany reviews grouped exercise interventions together and concluded that exercise 
can improve MSRF
40
. However, specific conclusions around the type of exercise is required if results 
are to be used in clinical practice.   
Endurance training (increase in endurance to sustain exercise for a greater duration) is currently not 
recommended in NICE guidelines
4
 and Tur
7
 did not discuss the endurance training. A total of 5179% 
(n=19/374) of studies concluded that endurance training has a significant improvement on MSRF. 
There were 9 duplications of different studies (23 studies in total)  This is stated ‘“with high moderate 
confidence’”.  
Aerobic training is currently recommended by NICE guidelines
4
. Other review evidence
7,354
 has 
identified some confusion into its effects. However, aA total of 680% (n=116/160) of studies in three 
reviews found aerobic training (changes in aerobic and cardiovascular capacity) had some benefit on 
MSRF which we state ‘with “moderatesome confidence’”. However, – overlapping definitions to 
endurance exercise meaning terms used by reviews may influenced the studies obtained and 
conclusions given). In addition, 14 studies excluding duplicates (n=4) were used in total affecting the 
overall power of the results.  had some benefit on MSRF which we state with “some confidence”.  
Comment [AS6]: needed 
Comment [AS7]: don’t need this – 
not sure what it gives 
Comment [PM8]: This was the 
review as 
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Yoga is recommended in NICE guidelines
4
 along with the MS Society UK
422
. A total of 81% of 
studies (n=18/22) found yoga to have a significant improvement on MSRF. However,However, it 
must be noted that there were 7 duplications of one study and there were 9 studies in total. Taking the 
NICE guidel that ines into consideration, this statement is made ‘concluded with “high moderate 
confidence’”.  
The NICE guidelines4 recommend progressive resistance training in a combined physical and 
behavioural program. Current Existing review evidence supports
7
 this. 14 studies excluding duplicates 
(n=5) were used in total. A total of 6853% (n=1316/1930) of studies found a significant improvement 
on MSRF with resistance training in 4 reviews  and considering the NICE guidelines the results are 
that is stated ‘with “somemoderate confidence’”.  
A combination of exercise/combined training is recommended in NICE guidelines4. Only 3 
duplications of studies were found. A total of 5287% (n=2013/235) of studies found that combined 
training had a significant improvement on MSRF in 5 reviews which is stated ‘with “some high 
confidence’”. It must be acknowledged that the combined training was different in each study and 
therefore large powered randomised studies with similar interventions should be examined to find the 
most effective intervention in combined training. Considering the heterogeneity of the data we 
stateconsider ‘with some confidence’ that combined training  that this intervention positively affects 
fatigueMSRF.  with “some confidence” due the heterogeneity of the interventions 
 
Currently not recommended Interventions not Currently Recommended 
Acupuncture 
Karpatkin376 found significant improvements in MSRF with acupuncture treatment. This is stated 
‘“with caution’” as the review was poorly conducted and  theand the included studies were of poor 
quality.  
 
 
Clinical Implications  
Below we detail evidence ‘with “high confidence’” of a beneficial effect on MSRF:  
Pharmacological Interventions 
At present, Tthere is currently no single drug that we would recommend. Considering the NICE 
guidelines, Amantadine is the only pharmacological treatment that is used in clinical practice for  
MSRFMSRF and therefore is continued to be used at present. However, the evidence to support its 
use is not strong. New RCTs to support its positive effects on fatigueMSRF should be conducted.and 
Ffurther research into the potential positive effects on Modafinil is neededwarranted.  
Non-Pharmacological Interventions 
Education is recommended as an effective treatment for MSRF. 
Recent evidence
44
 has identified the following education is required: (1) others  including (health care 
professionals, carers or family members) need to be educated about MSRF and be careful not to 
consider MSRF as equivalent to their own experiences fatigue, (2) patients would benefit from 
understanding and accepting the impact of MSRF (3) patients should be supported to plan activities of 
daily living and rest periods that can accommodate the MSRF.  
Comment [AS9]: how many 
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Endurance training and Yoga interventions have supporting evidence that allow us to recommend 
these interventions in MSRF treatment. 
Current cClinical guidelines for Yoga include:  
The evidence identified from this review suggests that Yoga was found in this review of reviews to 
have likely has a significant improvement on MSRF which is in correlation agreement the past NICE
4
 
guidelines which recommends Yoga for MSRF. with NICE guidelines4 in which ‘aerobic, balance and 
stretching exercises including yoga’ are recommended. The prescription of Yoga should include the 
following parameters: 
Frequency: 1-3 times per week (average 1)
5,343,2,321,323,3029,365 
Time: 60-90 mins
5,343,2,312,323,3029,365
 
Type: Iyengar
5,2,312,323,3029,356
, Hatha
312, 332,
, Unspecified
5,321,323,2930,356
, Tai-chi
323 
Current clinical guidelines
9,29,32,34 
for endurance training include: 
The evidence from this review suggested that endurance training improved MSRF, this is in 
agreementagrees with NICE
4
 guidelines. The prescription of endurance training should include the 
following parameters  building up sessions towards the following parameters (where studies are not 
reference no detail was given):  
Frequency: 2-5 days per week9,323,345 
Intensity: average percent of maximum heart rate during aerobic exercise 40-85% of HR
9,3029 
Time: 30 minutes per session
9,3029 
Type of exercise: walking9,323,2930, ergometric cycling 9,3029, cycling332, endurance type training 
devices
332
, lower limb endurance exercises
354
, circuits
3029
 and upper body ergometry
2930
. 
  
Limitations 
The following limitations are acknowledged: Most included participants had moderate to severe 
fatigue, thus findings may be most applicable to this group. The participants’ diagnosis was not listed 
in every review, thus the application of results to sub-types of MS is not possible. In addition, the 
gender most often was identified as female or unknown. Asano
25 
reported varying effects of 
interventions on different diagnosis, age and gender as covariates that impacted on the effectiveness 
of the intervention for in MSRF. The current results don’t consider the impact of these covariates. 
These factors will therefore impact the results found in the reviews of reviews. 
The inclusion criteria of the reviews were not always clear and therefore some inaccuracies in the data 
should be acknowledged. Furthermore, some interventions studied in this review of reviews were not 
designed to treat fatigueMSRF, or have a primary outcome measure related to MSRF.  and thus not 
being a primary outcome on which studies were conducted. This affects the specificity of the data and 
the accuracy of the conclusions made on interventions not primarily measuring MSRF. 
 Due to a lack of randomised control trials forms of bias likely influence and limit the internal or 
external validity of the results. Considering randomised controlled trials are criterion for efficacy and 
effectiveness of studies the importance of new studiesFurther adequately powered  being RCTs are 
needed to havegenerate the most accurate and reliable data on which to base conclusions.  The results 
may be limited by the synthesis techniques undertaken. The number of outcome measures along with 
poor psychometric properties may compromise the findings by limiting the ability of this review to 
Comment [AS10]: did they say 1 
paragraph or leave as is? If no 
comment leave as is 
Comment [AS11]: you say this at the 
end of paragraph 3 keep in? 
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identify benefits by domain of MSRF.  Furthermore, the included reviews contained studies that did 
not have fatigue as a primary outcome measure and therefore the interventions on MSRF may not be 
accurate creating false-positive and false negative results leading to misinterpretation of the data. 
Duplications of the articles across reviews were included. This could lead to a misrepresentation of 
the data. However, including the summaries of the data, there is still information that can be gathered 
from this review of reviews. 
 
Conclusion 
This current review of reviews has been able to recommend the use of education (energy conservation 
and fatigue management) and, yoga and endurance training as effective interventions for MSRF. 
Combined training was found to have strong evidence supporting its use in MSRF. However, the 
studies had dissimilar interventions and therefore the recommendation for combined training on this 
review cannot be made. Overall, Tthese recommendations are limited by data heterogeneity and 
specificity of the included outcome measures in studies to MSRF. We recommend further well-
powered RCTs with the following promising fatigue interventions: (1) for the pharmacological 
treatments of MSRF consideration to Amantadine and Modafinil and (2) for the non-pharmacological 
treatment of MSRF the non-pharmacological treatment ofconsideration to CBT and subtypes of 
exercise training. We recommend that further interventions be conducted.  
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